Intellia Therapeutics vs Trinity Biotech
NTLA and TRIB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NTLA and TRIB compare
Intellia Therapeutics grew revenue faster over the last twelve months (12.6% versus −28.9% for Trinity Biotech).
Trinity Biotech keeps more of each dollar of sales as profit, with a net margin of −85.4% compared with −672% at Intellia Therapeutics.
Intellia Therapeutics scores higher on the StockData Score (8 against 1 for Trinity Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NTLA | TRIB |
|---|---|---|
| Size and price | ||
| Market cap | $1.4B | – |
| Share price | $9.86 | $5.38 |
| Change, 1 year | 13.7% | −79.0% |
| Change, 5 years | −91.3% | −98.0% |
| Beta (5Y) | 1.64 | 3.56 |
| Employees | 377 | 287 |
| StockData Score | ||
| Total score | 8 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 23.2× | – |
| P/B | 1.9× | – |
| FCF yield | −25.2% | – |
| Fair value | $9.05 | – |
| Margin of safety | −8.9% | – |
| Growth | ||
| Revenue growth (TTM) | 12.6% (better) | −28.9% |
| Revenue growth, 5Y average | 3.1% (better) | −15.6% |
| Profitability | ||
| Gross margin | – | 38.6% |
| Operating margin | −712% | −36.1% (better) |
| Net margin | −672% | −85.4% (better) |
| FCF margin | −586% | −13.7% (better) |
| Return on equity | −6425% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −0.7× |
| Current ratio | 6.65 (better) | 0.25 |
| Altman Z-score | 0.91 | – |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 103% | 0.01% |
| Held by insiders | 2.0% | 51.7% |
| Insider net buying, 12 months | −$869K | – |
| Short interest, % of float | 32.3% | – |
Go deeper
- NTLA stock overview
- NTLA income statement
- NTLA valuation and score
- TRIB stock overview
- TRIB income statement
- TRIB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.